Hepatitis B Vaccine
13
1
1
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
69%
9 trials in Phase 3/4
83%
5 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (13)
Research on Clinical Recovery and Maintenance Strategies for CHB
Hepatitis B Vaccine Delivered Trans-dermally by MAP
Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients
Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients
The Immunogenicity and Persistence of Booster Dose With Hepatitis B Vaccine in College Students
Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B
Immunogenicity and Persistence of Hepatitis B Vaccination in HIV-Infected Patients
Research on Optimal Immunization Strategy of Hepatitis B Vaccine in Chronic Kidney Disease Population
Immunogenicity and Persistence of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients
Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.
Comparison of Immunization Quality Improvement Dissemination Study
Assessment of HBV Vaccine Immunity After 18 Years